Therapeutic potential of selective PDE inhibitors in asthma

Pulmonary Pharmacology and Therapeutics

Volumn 12, Issue 2, 1999, Pages 123-129

  Gantner, F ^a   Tenors, H ^a   Hatzelmann, A ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MOTAPIZONE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; ROLIPRAM; SIGUAZODAN;

ASTHMA; BRONCHUS MUSCLE; CONFERENCE PAPER; DENDRITIC CELL; EOSINOPHIL; HEADACHE; HEART ARRHYTHMIA; HUMAN; MACROPHAGE; MAST CELL; NAUSEA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TACHYCARDIA; VOMITING;

EID: 0033117705     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1999.0182     Document Type: Conference Paper

References (48)

1. Iyengar R. Gating by cyclic AMP: expanded role for an old signalling pathway. Science. 271:1996;461-463.
2. Houslay M D, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends in Biochem Sci. 22:1997;217-224.
3. Tenor H., Schudt C. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. In: Schudt C, Dent G, Rabe K F eds. Phosphodiesterase inhibitors. San Diego: Academic Press. 1996;21-40.
4. Bochert G., Bartel S., Beyerdörfer I., Küttner I., Szekeres L., Krause E G. Long lasting anti-adrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities. Mol Cell Biol. 132:1994;57-67.
5. Torphy T J. Phosphodiesterase Isoenzymes. Am J Resp. Crit Care Med. 157:1998;351-370.
6. Tenor H., Hatzelmann A., Wendel A., Schudt C. Identification of phosphodiesterase IV activity and its cyclic adenosine monophosphate-dependent up-regulation in a human keratinocyte cell line (HaCaT). J Invest Dermatol. 105:1995;70-74.
7. Jiang X., Li J., Paskind M., Epstein P M. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci. 93:1996;11236-11241.
8. Erdogan S., Houslay M D. Challenge of human Jurkat T-cells by the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating a novel PDE4A splice variant. Biochem J. 321:1997;165-175.
9. Rybalkin S D, Bornfeldt K E, Sonnenburg W K, Rybalkina I G, Kwak K S, Hanson K., Krebs E G, Beavo J A. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 100:1997;2611-2621.
10. Gantner F., Kupferschmidt R., Schudt C., Wendel A., Hatzelmann A. In vitro differentation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumor necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol. 121:1997;221-231.
11. Tenor H., Hatzelmann A., Kupferschmidt R., Stanciu L., Djukanovic R., Schudt C., Wendel A., Church M K, Shute J K. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy. 25:1997;625-633.
12. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 16:1995;370-389.
13. Gantner F., Tenor H., Gekeler V., Schudt C., Wendel A., Hatzelmann A. Phosphodiesterase profiles of highly purified human peripherial blood leukoytes populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol. 100:1997;527-535.
14. Li S H, Chan S C T A, Leung D Y M, Hanifin J. Synergistic effect of interleukin 4 and interferon-γ on monocyte phosphodiesterase activity. J Invest Dermatol. 99:1992;65-70.
15. Dongmin M A, Ping W U, Egan R W, Billah M M, Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol. 55:1999;50-57.
16. Ekholm D., Hemmer B., Gao G., Vergelli M., Martin R., Manganiello V. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J Immunol. 159:1997;1520-1529.
17. Suttorp N., Weber U., Welsch T., Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest. 91:1993;1421-1428.
18. Tenor H., Hatzelmann A., Church M K, Schudt C., Shute J K. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol. 118:1996;1727-1735.
19. Hatzelmann A., Tenor H., Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol. 114:1995;821-831.
20. Schudt C., Winder S., Forderkunz S., Hatzelmann A., Ullrich V. Influcence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Ca. Naunyn-Schmiedeberg's Arch Pharmacol. 344:1991;682-690.
21. Gantner, F, Schudt, C, Wendel, A, Hatzelmann, A, Characterization of the phosphodiesterase (PDE) pattern of in vitro generated human dendritic cells(DC) and the influence of PDE inhibitors on DC function, Pulm Pharmacol (submitted).
22. Hatzelmann A., Engelstätter R., Morley J., Mazzoni L. Enzymatic and functional aspects of dual-selective PDE3/4 inhibitors. In: Schudt C, Dent G, Rabe K F, eds. Phosphodiesterase Inhibitors. San Diego: Academic Press. 1996;147-161.
23. +T lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol. 118:1996;1945-1958.
24. Robicsek S., Blanchard D., Djeu Y., Krzanowski J., Szentivanyi A., Polson J. Multiple high affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol. 42:1991;869-877.
25. Essayan D M, Kagey-Sobotka A., Lichtenstein L M, Huang S K. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isoenzyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther. 282:1997;505-512.
26. +T lymphocytes. Clin Exp Allergy. 25:1995;616-624.
27. Weston M C, Anderson N., Peachell P T. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br J Pharmacol. 121:1997;287-295.
28. Suttorp N., Ehreiser P., Hippenstiel S., Fuhrmann M., Krull M., Tenor H., Schudt C. Hypermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung. 174:1996;181-194.
29. Rabe K., Tenor H., Dent G., Schudt C., Liebig S., Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol. 264:1996;L458-L464.
30. Cortijo J., Bou J., Beleta I., Llenas J., Morcillo E., Gristwood R W. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol. 108:1993;562-568.
31. Graves L M, Bornfeldt K E, Raines E W, Potts B C, MacDonald S G, Ross R., Krebs E G. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein-kinase in human arterial smooth muscle cells. Proc Natl Acad Sci. 90:1993;10300-10304.
32. Johnson-Mills K., Arauz E., Coffey R G, Krzanowsk Jr ?, Polson J B. Effect of Cl-930[3-(2H9-pyridazinone-4,5-dihydro-6-[1H-imidazolyl)phenyl]-5-methyl-monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation. Biochem Pharmacol. 56:1998;1065-1073.
33. m, rolipram-sensitive, cAMP-spezific phosphodiesterase from human brain. J Biol Chem. 268:1993;6470-6476.
34. Jacobitz S., McLaughlin M M, Livi G P, Burman M., Torphy T J. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol. 50:1996;891-899.
35. Rocque W J, Tian G., Wiseman J S, Holmes W D, Zajac-Thompson I., Willard D H, Patel I R, Wisely G B, Clay W C, Kadwell S H. et al. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry. 36:1997;14250-14261.
36. Souness J E, Griffin M., Maslen C., Ebsworth K., Scott L C, Pollock K., Palfreyman M N, Karlsson J A. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. Br J Pharmacol. 118:1996;649-658.
37. Barnette M S, Bartus J O, Burman M., Christensen S B, Cieslinski L B, Esser K M, Prabhakar U S, Rush J A, Torphy T J. Association of the anti-inflammatory activity of phosphodiesterase 4(PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem Pharmacol. 51:1996;949-956.
38. Souness J E, Houghton C., Sardar N., Withnall M T. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interaction with a "low-affinity" phosphodiesterase 4 conformer. Br J Pharmacol. 121:1997;743-750.
39. Schneider J J, Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol. 127:1986;105-115.
40. Souness J E. Characterization of different states PDE4 by rolipram and RP73401. In: Schudt C, Dent G, Rabe K F. eds. Phosphodiesterase Inhibitors. San Diego: Academic Press. 1996;173-185.
41. Torphy T J. Ariflo(SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and CLPD: from concept to clinic. Pulm Pharm Ther. 12:1999;131-135.
42. Packer M., Carver J., Rodeheffer R., Ivanhoe R., DiBianco R., Zeldis S., Hendrix G., Bommer W., Elkayam U., Kukin M. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group [see comments]. N Engl J Med. 325:1991;1468-1475.
43. Kajimoto K., Hagiwara N., Kasanuki H., Hosoda S. Contribution of phosphodiesterase isoenzymes to the regulation of the L-type calcium current in human cardiac myocytes. Br J Pharmacol. 121:1997;1549-1556.
44. Katz A M. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Col Cardiol. 19:1992;1622-1633.
45. Rivet-Bastide M., Vandecasteele G., Hatem S., Verde I., Benardéau A., Mercadier J J, Fischmeister R. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest. 99:1997;2710-2718.
46. Kirstein M., Rivet-Bastide M., Hatem S., Bénardeau A., Mercadier J J, Fischmeister R. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest. 95:1995;794-802.
47. Degerman E., Belfrage P., Manganiello V. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 272:1997;6823-6826.
48. Gantner F., Götz C., Gekeler V., Schudt C., Wendel A., Hatzelmann A. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol. 123:1998;1031-1038.